0R1F.IL

Bristol-Myers Squibb Company | Cotação de Ações

Última atualização24/09/2025, 11:43:57

PreçoUS$ 44,45

Variação (dia)-US$ 0,75 (-1.66%)▼

Min. 52 SemanasUS$ 42,98

Máx. 52 SemanasUS$ 63,17

Capitalização de mercado--

Endereço: 430 East 29th Street, New York, NY, 10016

Telefone: 212 546 4000

Funcionários: 34.300

BRISTOL-MYERS SQUIBB CO BRISTOL0R1F.IL

US$ 44,45

- 0,7511,7%

24/09/2025 11:43:57

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 44,45

Valor de mercado--

AberturaUS$ 46,27

Preço máximoUS$ 45,01

Preço mínimoUS$ 44,38

VolumeUS$ 5,5 mil

Fechamento anteriorUS$ 45,20

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Ações relacionadas

Pfizer Inc.

0Q1N.IL ▼0.20% | US$ 26,05

Sanofi

0O59.IL ▲0.15% | € 100,07

Roche Holding AG

0QOK.IL ▲0.50% | CHF 274,85

Novartis AG

0QLR.IL ▲0.86% | CHF 90,67

Gilead Sciences, Inc.

0QYQ.IL ▼0.45% | US$ 92,62

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.